3 completed. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 1 | Completed 1 |
Follow Memory Impairment: new trials by email Literature Review of Memory Impairment trials Research Report on Memory Impairment
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Diminishing Accelerated Long-term Forgetting in Mild Cognitive Impairment NITESGON, Lidocaine / Prilocaine Topical Cream, C5/C6 stimulation - Mild Cognitive Impairment, Memory Impairment | Phase 1 / Phase 2 | Completed | University of Dublin, Trinity College | 80 | 2022-09-01 | 2026-01-26 |
| Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults Roflumilast, Roflumilast placebo, Donepezil - Memory Impairment, Alzheimer's Disease | Phase 1 | Completed | AstraZeneca | 27 | 2014-01-01 | 2017-02-01 |
| The Effects of Minocycline in Humans Sugar pill, Minocycline - Memory Impairment | Phase 1 | Completed | Yale University | 10 | 2013-07-08 | 2019-09-19 |
Memory Disorders (3) · Alzheimer Disease (1) · Cognitive Dysfunction (1) · cyclopia sequence (1)
Nervous System Diseases (3) · Neurobehavioral Manifestations (3) · Neurologic Manifestations (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Mental Disorders (2) · Neurocognitive Disorders (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Cognition Disorders (1) · Dementia (1) · Neurodegenerative Diseases (1) · Tauopathies (1)
Anesthetics, Local (1) · Butylscopolammonium Bromide (1) · Donepezil (1) · Lidocaine (1) · Minocycline (1) · Roflumilast (1) · Scopolamine (1) · Sugars (1) · Tetracycline (1) · Transcutaneous Electric Nerve Stimulation (1)
AstraZeneca (1) · University of Dublin, Trinity College (1) · Yale University (1)
Ireland (1) · United Kingdom (1) · United States (1)
Mehmet Sofuoglu, M.D.,Ph.D. (1) · Sven Vanneste, PhD (1)